BBI Life Sciences Corporation provided group profit guidance for the six months ended June 30, 2018. The board of directors of the company hereby informs the shareholders of the company and potential investors that, based on the currently available unaudited management accounts of the Group and the preliminary assessment by the company's management, it is expected that the Group will record an increase in net profit of more than 30% for the six months ended June 30, 2018 as compared to the six months ended June 30, 2017. The expected increase in net profit is primarily attributed to the sustained and rapid development of the Group's main business and the significant narrowing of Bionics Co. Ltd.